292 related articles for article (PubMed ID: 29968906)
21. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R; Paranjape AN; Maity S; Aparicio A; Mani SA
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):229-238. PubMed ID: 29981816
[TBL] [Abstract][Full Text] [Related]
22. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
23. The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin.
Huang X; Borgström B; Stegmayr J; Abassi Y; Kruszyk M; Leffler H; Persson L; Albinsson S; Massoumi R; Scheblykin IG; Hegardt C; Oredsson S; Strand D
ACS Cent Sci; 2018 Jun; 4(6):760-767. PubMed ID: 29974072
[TBL] [Abstract][Full Text] [Related]
24. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.
Dongre A; Weinberg RA
Nat Rev Mol Cell Biol; 2019 Feb; 20(2):69-84. PubMed ID: 30459476
[TBL] [Abstract][Full Text] [Related]
25. The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis.
Villanueva F; Araya H; Briceño P; Varela N; Stevenson A; Jerez S; Tempio F; Chnaiderman J; Perez C; Villarroel M; Concha E; Khani F; Thaler R; Salazar-Onfray F; Stein GS; van Wijnen AJ; Galindo M
J Cell Physiol; 2019 Aug; 234(8):13659-13679. PubMed ID: 30637720
[TBL] [Abstract][Full Text] [Related]
26. Loss of histone methyltransferase Ezh2 stimulates an osteogenic transcriptional program in chondrocytes but does not affect cartilage development.
Camilleri ET; Dudakovic A; Riester SM; Galeano-Garces C; Paradise CR; Bradley EW; McGee-Lawrence ME; Im HJ; Karperien M; Krych AJ; Westendorf JJ; Larson AN; van Wijnen AJ
J Biol Chem; 2018 Dec; 293(49):19001-19011. PubMed ID: 30327434
[No Abstract] [Full Text] [Related]
27. Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator.
Karamanou K; Franchi M; Vynios D; Brézillon S
Semin Cancer Biol; 2020 May; 62():125-133. PubMed ID: 31401293
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
Nedeljković M; Damjanović A
Cells; 2019 Aug; 8(9):. PubMed ID: 31443516
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal Transition and Cancer Stem Cells: At the Crossroads of Differentiation and Dedifferentiation.
Wang H; Unternaehrer JJ
Dev Dyn; 2019 Jan; 248(1):10-20. PubMed ID: 30303578
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer stem cells: Biology and therapeutic implications.
Butti R; Gunasekaran VP; Kumar TVS; Banerjee P; Kundu GC
Int J Biochem Cell Biol; 2019 Feb; 107():38-52. PubMed ID: 30529656
[TBL] [Abstract][Full Text] [Related]
31. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance.
Palomeras S; Ruiz-Martínez S; Puig T
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200262
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities.
Zhang Y; Weinberg RA
Front Med; 2018 Aug; 12(4):361-373. PubMed ID: 30043221
[TBL] [Abstract][Full Text] [Related]
33. Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer.
Inayatullah M; Mahesh A; Turnbull AK; Dixon JM; Natrajan R; Tiwari VK
EMBO Mol Med; 2024 Apr; 16(4):823-853. PubMed ID: 38480932
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer.
Zheng W; Peng W; Qian F; Zhang M; Duan B; Fan Z; Xie Y; Fu X
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38456956
[TBL] [Abstract][Full Text] [Related]
35. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin as a Potential Treatment Option in Canine Mammary Tumors.
Gherman ML; Zanoaga O; Budisan L; Raduly L; Berindan-Neagoe I
Vet Sci; 2023 Nov; 10(11):. PubMed ID: 37999477
[TBL] [Abstract][Full Text] [Related]
37. Multi-modal transcriptomic analysis unravels enrichment of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer.
Sahoo S; Ramu S; Nair MG; Pillai M; San Juan BP; Milioli HZ; Mandal S; Naidu CM; Mavatkar AD; Subramaniam H; Neogi AG; Chaffer CL; Prabhu JS; Somarelli JA; Jolly MK
bioRxiv; 2023 Oct; ():. PubMed ID: 37873432
[TBL] [Abstract][Full Text] [Related]
38. A literature review: mechanisms of antitumor pharmacological action of leonurine alkaloid.
Cao Q; Wang Q; Wu X; Zhang Q; Huang J; Chen Y; You Y; Qiang Y; Huang X; Qin R; Cao G
Front Pharmacol; 2023; 14():1272546. PubMed ID: 37818195
[TBL] [Abstract][Full Text] [Related]
39. Understanding and leveraging phenotypic plasticity during metastasis formation.
Shah S; Philipp LM; Giaimo S; Sebens S; Traulsen A; Raatz M
NPJ Syst Biol Appl; 2023 Oct; 9(1):48. PubMed ID: 37803056
[TBL] [Abstract][Full Text] [Related]
40. Prediction of prognosis and immunotherapy response in breast cancer based on neutrophil extracellular traps-related classification.
Zhao J; Xie X
Front Mol Biosci; 2023; 10():1165776. PubMed ID: 37304069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
